



**teriparatide (Forsteo®)**

**Eli Lilly & Co Ltd**

**January 2009**

**Appraisal notice to NHS Wales**

**Teriparatide (Forsteo®) has not been endorsed for use within NHS Wales for the treatment of osteoporosis associated with glucocorticoid therapy in women and men at increased risk of fractures.**

**The holder of the marketing authorisation has not made a submission to AWMSG for the appraisal of teriparatide (Forsteo®) for the above indication. As a result, AWMSG cannot provide advice to the Minister for Health and Social Services.**

AWMSG takes into account the NICE future work programme when considering whether a product will be appraised. AWMSG does not normally consider appraising a product if NICE intends to publish their final appraisal of the same product within a 18 month period from receipt of Form B. i.e. approx 12 months from the projected AWMSG appraisal date. AWMSG advice is interim to that of NICE, should NICE subsequently publish guidance.

This notice is provided for information to NHS Wales. In the absence of guidance issued by NICE or AWMSG clinicians should continue to exercise their clinical judgement (unless there is evidence not to do so) when prioritising for an individual patient. This should be in consultation with the patient and/or guardian or carer, based on the best available evidence.